1.Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection.
Gut and Liver 2015;9(6):809-810
No abstract available.
Amoxicillin/*therapeutic use
;
Anti-Bacterial Agents/*therapeutic use
;
Anti-Ulcer Agents/*therapeutic use
;
Female
;
Fluoroquinolones/*therapeutic use
;
Helicobacter Infections/*drug therapy
;
Humans
;
Male
;
Metronidazole/*therapeutic use
;
Organometallic Compounds/*therapeutic use
;
Rabeprazole/*therapeutic use
;
Tetracycline/*therapeutic use
2.Clinical Effects of Gemifloxacin on the Delay of Tuberculosis Treatment.
Seo Yun KIM ; Jae Joon YIM ; Jong Sun PARK ; Sung Soo PARK ; Eun Young HEO ; Chang Hoon LEE ; Hee Soon CHUNG ; Deog Kyeom KIM
Journal of Korean Medical Science 2013;28(3):378-382
Although gemifloxacin has low in vitro activity against Mycobacterium tuberculosis, the effect of gemifloxacin on the delay of tuberculosis (TB) treatment has not been validated in a clinical setting. The study group included patients with culture-confirmed pulmonary TB who initially received gemifloxacin for suspected community-acquired pneumonia (CAP). Two control groups contained patients treated with other fluoroquinolones or nonfluoroquinolone antibiotics. Sixteen cases were treated with gemifloxacin for suspected CAP before TB diagnosis. Sixteen and 32 patients were treated with other fluoroquinolones and nonfluoroquinolones, respectively. The median period from the initiation of antibiotics to the administration of anti-TB medication was nine days in the gemifloxacin group, which was significantly different from the other fluoroquinolones group (35 days). The median times for the nonfluoroquinolone group and the gemifloxacin group were not significantly different. There were no significant differences between the gemifloxacin and other fluoroquinolone group in terms of symptomatic and radiographic improvements. However, the frequency of radiographic improvement in the other fluoroquinolones group tended to be higher than in the gemifloxacin group. Gemifloxacin might be the preferred fluoroquinolone for treating CAP, to alleviate any concerns about delaying TB treatment.
Adult
;
Aged
;
Anti-Bacterial Agents/*therapeutic use
;
Case-Control Studies
;
Fluoroquinolones/*therapeutic use
;
Humans
;
Middle Aged
;
Naphthyridines/*therapeutic use
;
Pneumonia/complications/diagnosis
;
Tuberculosis/complications/*drug therapy/radiography
3.Sympathetic ophthalmia in an infected post-scleral buckling eye.
Jona M B SY-ONGKEKO ; Archimedes L D AGAHAN ; Juan S LOPEZ ; Jacinto U DY-LIACCO
Annals of the Academy of Medicine, Singapore 2011;40(3):147-148
Adrenal Cortex Hormones
;
therapeutic use
;
Aged
;
Anti-Infective Agents
;
therapeutic use
;
Anti-Inflammatory Agents
;
therapeutic use
;
Atropine
;
therapeutic use
;
Dexamethasone
;
therapeutic use
;
Eye Infections
;
complications
;
drug therapy
;
Female
;
Fluoroquinolones
;
therapeutic use
;
Glucocorticoids
;
therapeutic use
;
Humans
;
Mydriatics
;
therapeutic use
;
Ophthalmia, Sympathetic
;
drug therapy
;
etiology
;
Prednisolone
;
therapeutic use
;
Scleral Buckling
;
adverse effects
;
Triamcinolone
;
therapeutic use
4.Qianlie Jiedu capsule combined with rufloxacin for chronic prostatitis: a randomized double-blind controlled clinical trial.
Jian-Chun XU ; Qi-Ming LU ; Li-Jie FU ; Yu-Ping CHEN
National Journal of Andrology 2010;16(2):183-186
OBJECTIVEFew double-blind controlled trials have been reported on Chinese patent medicines for the treatment of chronic prostatitis. The purpose of this study was to investigate the therapeutic efficacy of Qianlie Jiedu Capsule for chronic prostatitis (CP) by the randomized double-blind controlled method.
METHODSEighty CP patients were equally randomized into an experimental and a control group, the former treated with Qianlie Jiedu Capsule + Rufloxacin, and the latter given placebo + Rufloxacin, both for 4 weeks. All the patients were evaluated by NIH-CPSI and EPS examination before and after the medication.
RESULTSAfter 4-week treatment, the total score of NIH-CPSI and the scores of pain, voiding symptoms and quality of life were significantly decreased in both groups compared with the baseline (P < 0.05), so did the leukocyte count in EPS (P < 0.05). And the experimental group showed significant drops in the above scores as compared with the control (P < 0.05), except in the leukocyte count in EPS (P > 0.05).
CONCLUSIONQianlie Jiedu Capsule combined with Rufloxacin is highly effective for CP by relieving pain and voiding symptoms,decreasing the leukocyte count in EPS and improving the life quality of the patients.
Adolescent ; Adult ; Chronic Disease ; Double-Blind Method ; Drugs, Chinese Herbal ; therapeutic use ; Fluoroquinolones ; therapeutic use ; Humans ; Male ; Middle Aged ; Phytotherapy ; Prostatitis ; drug therapy ; Young Adult
5.Increasing Prevalence of Vancomycin-Resistant Enterococci, and Cefoxitin-, Imipenem- and Fluoroquinolone-Resistant Gram-Negative Bacilli: A KONSAR Study in 2002.
Kyungwon LEE ; Young Ah KIM ; Yeon Joon PARK ; Hye Soo LEE ; Moon Yeun KIM ; Eui Chong KIM ; Dongeun YONG ; Yunsop CHONG
Yonsei Medical Journal 2004;45(4):598-608
Continued antimicrobial resistance surveillance can provide valuable information for the empirical selection of antimicrobial agents for patient treatment, and for resistance control. In this 6th annual study for 2002, the susceptibility data at 39 Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR) hospitals were analyzed. Resistance rates of S. aureus were 67% to oxacillin, and 58% to clindamycin. The ampicillin and vancomycin resistance rates of E. faecium were 89% and 16%, respectively. To penicillin, 71% of S. pneumoniae were nonsusceptible. Resistance rates of E. coli were 11% to cefotaxime, 8% to cefoxitin, and 34% to fluoroquinolone, and those of K. pneumoniae were 22% to ceftazidime, and 16% to cefoxitin. Lowest resistance rates to cephalosporins shown by E. cloacae and S. marcescens were to cefepime, 7% and 17%, respectively. This is the first KONSAR surveillance, which detected imipenem-resistant E. coli and K. pneumoniae. To imipenem, 22% of P. aeruginosa and 9% of Acinetobacter spp. were resistant. Trends of resistances showed a slight reduction in MRSA and in penicillin- nonsusceptible S. pneumoniae, but an increase in ampicillin-resistant E. faecium. Ampicillin-resistant E. coli and H. influenzae remained prevalent. Compared to the previous study, amikacin- and fluoroquinolone- resistant Acinetobacter spp. increased to 60% and 62%, respectively. Ceftazidime- resistant K. pneumoniae decreased slightly, and imipenem- resistant P. aeruginosa and Acinetobacter spp., and vancomycin-resistant E. faecium increased. In conclusion, vancomycin-resistant E. faecium, cefoxitin-resistant E. coli and K. pneumoniae, and imipenem-resistant P. aeruginosa and Acinetobacter spp. increased gradually, and imipenem- resistant E. coli and K. pneumoniae appeared for the first time. Continued surveillance is required to prevent further spread of these serious resistances.
Anti-Bacterial Agents/*therapeutic use
;
Cefoxitin/*therapeutic use
;
Drug Resistance, Bacterial
;
Enterococcus/*drug effects
;
Fluoroquinolones/therapeutic use
;
Gram-Negative Bacterial Infections/*drug therapy/*epidemiology
;
Gram-Positive Bacterial Infections/drug therapy/epidemiology
;
Humans
;
Imipenem/therapeutic use
;
Korea/epidemiology
;
Prevalence
;
*Vancomycin Resistance
6.Epithelial Wound Healing after Cataract Surgery Comparing Two Different Topical Fluoroquinolones.
Kyung Eun HAN ; Woo Suk CHUNG ; Tae Im KIM ; Sekyung KIM ; Terry KIM ; Eung Kweon KIM
Yonsei Medical Journal 2014;55(1):197-202
PURPOSE: To compare the epithelial wound healing response of two preservative-free fluoroquinolones, moxifloxacin and levofloxacin, in patients who underwent cataract surgery. MATERIALS AND METHODS: In this prospective, evaluator-masked, randomized clinical trial, 59 eyes of 50 patients who underwent cataract surgery were enrolled. Patients were randomized to receive moxifloxacin 0.5% (n=32 eyes) or levofloxacin 0.5% (n=27 eyes). All patients instilled moxifloxacin or levofloxain four times daily for 1 week prior to surgery and 2 weeks after surgery. The epithelial wound healing status in the corneal incision site was scanned with a raster scan mode of fourier-domain optical coherence tomography (FD-OCT). The number of eyes showing epithelial defect images and average number of corneal epithelial defect cuts per eye were compared between groups. All patients were evaluated on postoperative days 1, 2, 3, and 10. RESULTS: On postoperative days 1, 2, and 3, the number of eyes showing epithelial defects in FD-OCT was not statistically different (all p>0.05). The average number of corneal epithelial defect cuts was also not statistically different between the two groups (all p>0.05). No eyes showed epithelial defects on postoperative day 10 in either group. CONCLUSION: There were no differences on epithelial wound healing comparing these two different fluoroquinolones at the incision site of cataract surgery.
Aged
;
Aza Compounds/therapeutic use
;
Cataract Extraction
;
Cornea/drug effects/*surgery
;
Female
;
Fluoroquinolones/*therapeutic use
;
Humans
;
Levofloxacin/therapeutic use
;
Male
;
Middle Aged
;
Quinolines/therapeutic use
;
Tomography, Optical Coherence
;
Wound Healing/*drug effects
7.Proactive infection control measures to prevent nosocomial transmission of carbapenem-resistant Enterobacteriaceae in a non-endemic area.
Vincent Chi-Chung CHENG ; Jasper Fuk-Woo CHAN ; Sally Cheuk-Ying WONG ; Jonathan Hon-Kwan CHEN ; Josepha Wai-Ming TAI ; Mei-Kum YAN ; Grace See-Wai KWAN ; Herman TSE ; Kelvin Kai-Wang TO ; Pak-Leung HO ; Kwok-Yung YUEN
Chinese Medical Journal 2013;126(23):4504-4509
BACKGROUNDIdentification of hospitalized carbapenem-resistant Enterobacteriaceae (CRE)-positive patient is important in preventing nosocomial transmission. The objective of this study was to illustrate the implementation of proactive infection control measures in preventing nosocomial transmission of CRE in a healthcare region of over 3200 beds in Hong Kong between October 1, 2010 and December 31, 2011.
METHODSThe program included active surveillance culture in patients with history of medical tourism with hospitalization and surgical operation outside Hong Kong within 12 months before admission, and "added test" as an opportunistic CRE screening in all fecal specimens submitted to the laboratory. Outbreak investigation and contact tracing were conducted for CRE-positive patients. Serial quantitative culture was performed on CRE-positive patients and the duration of fecal carriage of CRE was analyzed.
RESULTSDuring the study period, a total of 6533 patients were screened for CRE, of which 76 patients were positive (10 from active surveillance culture, 65 from "added test", and 1 secondary case from contact tracing of 223 patients with no nosocomial outbreak), resulting in an overall rate of CRE fecal carriage of 1.2%. The median time of fecal carriage of CRE was 43 days (range, 13-119 days). Beta-lactam-beta-lactamase-inhibitors, cephalosporins, and fluoroquinolones were associated significantly with high fecal bacterial load when used 90 days before CRE detection, while use of cephalosporins, carbapenems, and fluoroquinolones after CRE detection are significantly associated with longer duration of carriage. The duration of fecal carriage of CRE also correlates significantly with the initial fecal bacterial load (Pearson correlation: 0.53; P = 0.02).
CONCLUSIONProactive infection control measures by enhanced surveillance program identify CRE-positive patients and data obtained are useful for the planning of and resource allocation for CRE control.
Anti-Bacterial Agents ; therapeutic use ; Carbapenems ; therapeutic use ; Cephalosporins ; therapeutic use ; Drug Resistance, Bacterial ; Enterobacteriaceae ; drug effects ; Enterobacteriaceae Infections ; prevention & control ; transmission ; Fluoroquinolones ; therapeutic use ; Humans ; Infection Control ; methods
8.Endogenous lipoid pneumonia associated with Legionella pneumophila serogroup 1.
Singapore medical journal 2013;54(3):e66-7
Endogenous lipoid pneumonia is an uncommon condition. This is a report of a 29-year-old woman diagnosed with endogenous lipoid pneumonia associated with Legionella pneumophila serogroup 1 infection. The patient's endogenous lipoid pneumonia resolved completely after treatment for Legionella pneumophila infection. This suggests that early diagnosis and aggressive treatment of the underlying infection may prevent any long-term sequelae of lipoid pneumonia.
Adult
;
Anti-Bacterial Agents
;
therapeutic use
;
Aza Compounds
;
therapeutic use
;
Azithromycin
;
therapeutic use
;
Female
;
Fluoroquinolones
;
Humans
;
Legionella pneumophila
;
classification
;
Legionnaires' Disease
;
diagnosis
;
drug therapy
;
microbiology
;
Pneumonia, Lipid
;
diagnosis
;
drug therapy
;
microbiology
;
Quinolines
;
therapeutic use
;
Treatment Outcome
9.Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
Tieying SUN ; Li SUN ; Rongmei WANG ; Xiaoping REN ; Dong-Jiang SUI ; Chun PU ; Yajuan REN ; Ying LIU ; Zhuo YANG ; Fengzhi LI
Chinese Medical Journal 2014;127(7):1201-1205
BACKGROUNDCommunity-acquired pneumonia (CAP) is a common infectious disease throughout the world and the incidence continues to grow as the population ages. Aspiration is an important pathogenic mechanism for pneumonia in the elderly and the management of patients with community-acquired pneumonia with aspiration factors is a major medical problem. Our study aimed to assess whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors.
METHODSIn this prospective, multicenter, open-label, randomized controlled trial, 77 patients with mild-to-moderate community-acquired pneumonia with aspiration factors were enrolled and randomly assigned to receive moxifloxacin or levofloxacin plus metronidazole. The primary efficacy variables were clinical outcomes in evaluable patients at a follow-up visit 7 to 14 days after the end of therapy.
RESULTSSeven days after the end of therapy a clinical cure was achieved for 76.7% (23 of 37) of efficacy-evaluable patients in the moxifloxacin group and 51.7% (15 of 40) of patients in the levofloxacin plus metronidazole group. There was a significant difference between the two groups (χ(2) = 4.002, P < 0.05). Bacteriological success rates were similar in the moxifloxacin group (93.3%) and levofloxacin plus metronidazole group (96.4%), there was no significant difference between the two groups (P > 0.05). The overall adverse event rate was 10.8% (4/37) in the moxifloxacin group versus 17.5% (7/40) in the levofloxacin plus metronidazole group, there was no significant difference between the two groups (P > 0.05). No serious adverse events were observed.
CONCLUSIONSMoxifloxacin is effective and safe for treatment of community-acquired pneumonia with aspiration factors. And the regimen of moxifloxacin monotherapy is more convenient compared with levofloxacin plus metronidazole.
Aged ; Aged, 80 and over ; Anti-Bacterial Agents ; therapeutic use ; Community-Acquired Infections ; drug therapy ; Female ; Fluoroquinolones ; therapeutic use ; Humans ; Levofloxacin ; therapeutic use ; Male ; Metronidazole ; therapeutic use ; Middle Aged ; Pneumonia ; drug therapy ; Prospective Studies
10.Gemifloxacin for the treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis: a meta-analysis of randomized controlled trials.
Lei ZHANG ; Rui WANG ; Matthew E FALAGAS ; Falagas E MATTHEW ; Liang-an CHEN ; You-ning LIU
Chinese Medical Journal 2012;125(4):687-695
BACKGROUNDGemifloxacin is a fluoroquinolone antibiotic with broad spectrum of antibacterial activity. The aim of the study was to evaluate the comparative effectiveness and safety of gemifloxacin for the treatment of patients with community-acquired pneumonia (CAP) or acute exacerbation of chronic bronchitis (AECB).
METHODSWe performed a meta-analysis of randomized controlled trials (RCTs) comparing gemifloxacin with other approved antibiotics. The PubMed, EMBASE, Chinese Biomedical Literature Database and the Cochrane Central Register of Controlled Trials were searched, with no language restrictions.
RESULTSTen RCTs, comparing gemifloxacin with other quinolones (in 5 RCTs) and β-lactams and/or macrolides (in 5 RCTs), involving 3940 patients, were included in this meta-analysis. Overall, the treatment success was higher for gemifloxacin when compared with other antibiotics (odds ratio 1.39, 95% confidence interval 1.15 - 1.68 in intention-to-treat patients, and 1.33, 1.02 - 1.73 in clinically evaluable patients). There was no significant difference between the compared antibiotics regarding microbiological success (1.19, 0.84 - 1.68) or all-cause mortality (0.82, 0.41 - 1.63). The total drug related adverse events were similar for gemifloxacin when compared with other quinolones (0.89, 0.56 - 1.41), while lower when compared with β-lactams and/or macrolides (0.71, 0.57 - 0.89). In subgroup analyses, administration of gemifloxacin was associated with fewer cases of diarrhoea and more rashes compared with other antibiotics (0.66, 0.48 - 0.91, and 2.36, 1.18 - 4.74, respectively).
CONCLUSIONSThe available evidence suggests that gemifloxacin 320 mg oral daily is equivalent or superior to other approved antibiotics in effectiveness and safety for CAP and AECB. The development of rash represents potential limitation of gemifloxacin.
Anti-Bacterial Agents ; therapeutic use ; Bronchitis, Chronic ; drug therapy ; Community-Acquired Infections ; drug therapy ; Fluoroquinolones ; therapeutic use ; Humans ; Naphthyridines ; therapeutic use ; Pneumonia ; drug therapy ; Quinolones ; therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome